Natera Overview
Latest ROE for Natera: -10.56% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-10.56%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Natera (NTRA) currently reports a ROE of -10.56%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Natera's ROE history and peer comparisons.
Natera's ROE of -10.56% is lower than the Healthcare sector average of 21.28%. That is roughly 149.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Natera's current -10.56% should be judged against Healthcare norms (sector average: 21.28%) and against NTRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -10.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Natera, and consider following NTRA for alerts when major investors trade the stock.
Natera is classified in the Healthcare sector. On ROE, it currently shows -10.56% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NTRA with unrelated industries.
